DD297916A5 - Niedrig-viskose, hochkonzentrierte surfactant-suspensionen - Google Patents

Niedrig-viskose, hochkonzentrierte surfactant-suspensionen Download PDF

Info

Publication number: DD297916A5
Authority: DD; German Democratic Republic
Prior art keywords: mmol; surfactant; ions; calcium; suspensions
Prior art date: 1989-07-04

Application number

DD90342432A

Other languages

German (de)

English (en)

Inventor

Bernd Disse

Eberhard Weller

Robert Becker

Original Assignee

��K@��@��@��@��@��@��k��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-07-04

Filing date

1990-07-02

Publication date

1992-01-30

1990-07-02 Application filed by ��K@��@��@��@��@��@��k�� filed Critical ��K@��@��@��@��@��@��k��

1992-01-30 Publication of DD297916A5 publication Critical patent/DD297916A5/de

Links

239000004094 surface-active agent Substances 0.000 title claims abstract description 86
239000000725 suspension Substances 0.000 title claims abstract description 64
239000011575 calcium Substances 0.000 claims abstract description 86
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 51
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 36
239000011780 sodium chloride Substances 0.000 claims abstract description 29
239000000375 suspending agent Substances 0.000 claims abstract description 21
229910001425 magnesium ion Inorganic materials 0.000 claims abstract description 15
229910001424 calcium ion Inorganic materials 0.000 claims abstract description 11
238000009256 replacement therapy Methods 0.000 claims abstract description 8
JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims abstract description 6
229910052791 calcium Inorganic materials 0.000 claims description 31
235000002639 sodium chloride Nutrition 0.000 claims description 30
150000002632 lipids Chemical class 0.000 claims description 18
239000011777 magnesium Substances 0.000 claims description 18
150000002500 ions Chemical class 0.000 claims description 15
150000003904 phospholipids Chemical class 0.000 claims description 15
239000000243 solution Substances 0.000 claims description 15
238000000034 method Methods 0.000 claims description 14
238000002360 preparation method Methods 0.000 claims description 13
210000004072 lung Anatomy 0.000 claims description 12
108090000623 proteins and genes Proteins 0.000 claims description 11
102000004169 proteins and genes Human genes 0.000 claims description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
241000283690 Bos taurus Species 0.000 claims description 8
239000008346 aqueous phase Substances 0.000 claims description 6
239000012074 organic phase Substances 0.000 claims description 6
230000008569 process Effects 0.000 claims description 6
239000007864 aqueous solution Substances 0.000 claims description 5
238000009826 distribution Methods 0.000 claims description 5
238000000746 purification Methods 0.000 claims description 5
239000012530 fluid Substances 0.000 claims description 4
229910052749 magnesium Inorganic materials 0.000 claims description 4
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 claims description 3
238000004140 cleaning Methods 0.000 claims description 3
239000003960 organic solvent Substances 0.000 claims description 3
208000023504 respiratory system disease Diseases 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 2
230000001476 alcoholic effect Effects 0.000 claims 1
239000012267 brine Substances 0.000 claims 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 claims 1
239000007966 viscous suspension Substances 0.000 claims 1
208000018569 Respiratory Tract disease Diseases 0.000 abstract 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 12
239000001110 calcium chloride Substances 0.000 description 12
229910001628 calcium chloride Inorganic materials 0.000 description 12
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
208000032571 Infant acute respiratory distress syndrome Diseases 0.000 description 6
206010028974 Neonatal respiratory distress syndrome Diseases 0.000 description 6
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000003580 lung surfactant Substances 0.000 description 6
201000002652 newborn respiratory distress syndrome Diseases 0.000 description 6
238000003860 storage Methods 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
239000000203 mixture Substances 0.000 description 5
238000011835 investigation Methods 0.000 description 4
239000002245 particle Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
206010036590 Premature baby Diseases 0.000 description 3
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 3
201000000028 adult respiratory distress syndrome Diseases 0.000 description 3
238000013459 approach Methods 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
238000011068 loading method Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
238000002604 ultrasonography Methods 0.000 description 3
238000010626 work up procedure Methods 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
239000003708 ampul Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000000605 extraction Methods 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
210000003754 fetus Anatomy 0.000 description 2
239000008103 glucose Substances 0.000 description 2
238000002955 isolation Methods 0.000 description 2
159000000003 magnesium salts Chemical class 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000011160 research Methods 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
201000004193 respiratory failure Diseases 0.000 description 2
239000007858 starting material Substances 0.000 description 2
BHMLFPOTZYRDKA-IRXDYDNUSA-N (2s)-2-[(s)-(2-iodophenoxy)-phenylmethyl]morpholine Chemical compound IC1=CC=CC=C1O[C@@H](C=1C=CC=CC=1)[C@H]1OCCNC1 BHMLFPOTZYRDKA-IRXDYDNUSA-N 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
206010003598 Atelectasis Diseases 0.000 description 1
206010006482 Bronchospasm Diseases 0.000 description 1
206010010219 Compulsions Diseases 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 1
208000000203 Hyaline Membrane Disease Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
208000004756 Respiratory Insufficiency Diseases 0.000 description 1
206010038687 Respiratory distress Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
206010001053 acute respiratory failure Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000007885 bronchoconstriction Effects 0.000 description 1
QSLUWZMIMXNLJV-UHFFFAOYSA-L calcium methanol dichloride Chemical compound [Cl-].[Cl-].[Ca+2].OC QSLUWZMIMXNLJV-UHFFFAOYSA-L 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
238000002485 combustion reaction Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
238000007865 diluting Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000001035 drying Methods 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
-1 for example Chemical class 0.000 description 1
235000021588 free fatty acids Nutrition 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000005457 ice water Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000002386 leaching Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000000691 measurement method Methods 0.000 description 1
239000012454 non-polar solvent Substances 0.000 description 1
239000003921 oil Substances 0.000 description 1
238000005457 optimization Methods 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
238000005375 photometry Methods 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000002028 premature Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
238000007873 sieving Methods 0.000 description 1
238000000527 sonication Methods 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
238000009423 ventilation Methods 0.000 description 1
238000000196 viscometry Methods 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Pulmonology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Pharmacology & Pharmacy (AREA)
Cell Biology (AREA)
Animal Behavior & Ethology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Toxicology (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Physiology (AREA)
Developmental Biology & Embryology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Virology (AREA)
Epidemiology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Detergent Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Artificial Filaments (AREA)
Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DD90342432A 1989-07-04 1990-07-02 Niedrig-viskose, hochkonzentrierte surfactant-suspensionen DD297916A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE3921954A DE3921954A1 (de)	1989-07-04	1989-07-04	Niedrig-viskose, hochkonzentrierte surfactant-suspension

Publications (1)

Publication Number	Publication Date
DD297916A5 true DD297916A5 (de)	1992-01-30

Family

ID=6384269

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD90342432A DD297916A5 (de)	1989-07-04	1990-07-02	Niedrig-viskose, hochkonzentrierte surfactant-suspensionen

Country Status (24)

Country	Link
US (1)	US5552161A (da)
EP (1)	EP0406732B1 (da)
JP (1)	JP3103582B2 (da)
KR (1)	KR0162642B1 (da)
AT (1)	ATE122891T1 (da)
AU (1)	AU623538B2 (da)
CA (1)	CA2020209C (da)
DD (1)	DD297916A5 (da)
DE (2)	DE3921954A1 (da)
DK (1)	DK0406732T3 (da)
ES (1)	ES2072940T3 (da)
FI (1)	FI95655C (da)
HK (1)	HK1000277A1 (da)
HU (1)	HU205004B (da)
IE (1)	IE68448B1 (da)
IL (1)	IL94961A (da)
NO (1)	NO180620C (da)
NZ (2)	NZ242869A (da)
PH (1)	PH30232A (da)
PL (1)	PL164434B1 (da)
PT (1)	PT94574B (da)
RU (1)	RU2077880C1 (da)
UA (1)	UA26313A (da)
ZA (1)	ZA905182B (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4418936A1 (de) *	1994-05-31	1996-02-08	Byk Gulden Lomberg Chem Fab	Polypeptid
US6129934A (en) *	1995-06-07	2000-10-10	Ony, Inc.	Modification of animal lung surfactant for treating respiratory disease due to lung surfactant deficiency or dysfunction
US6172203B1 (en) *	1996-02-07	2001-01-09	Alfredo Adolfo Hager	Method for extracting and purifying pulmonary surfactant
US7053176B1 (en)	1999-09-16	2006-05-30	Altana Pharma Ag	Combination of C1-INH and lung surfactant for the treatment of respiratory disorders
EP1249244A1 (en)	2001-04-13	2002-10-16	Universiteit Gent	Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease
AU2002338882B2 (en)	2001-10-11	2008-04-03	Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V.	Novel use of pulmonary surfactant
US8337815B2 (en) *	2004-12-23	2012-12-25	Discovery Laboratories, Inc.	Pulmonary surfactant formulations
US7776619B2 (en)	2005-05-11	2010-08-17	Yamasa Corporation	Method of stabilizing pulmonary surfactant protein
US8048043B2 (en) *	2007-06-08	2011-11-01	Chiesi Farmaceutici S. P. A.	Method of administration of a pulmonary surfactant

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS55160721A (en) *	1979-06-02	1980-12-13	Tokyo Tanabe Co Ltd	Pulmonary surfactant ta-546, its preparation, and remedy for pulmonary hyaline membrane syndrome comprising it as active constituent
EP0110498B2 (en) *	1982-11-22	1991-09-18	Teijin Limited	Artificial lung surfactant and remedy for respiratory distress syndrome containing it as active principle
JPS59164724A (ja) *	1983-03-10	1984-09-17	Tokyo Tanabe Co Ltd	サ−フアクタント及びそれを含有する呼吸窮迫症候群治療剤
CS938384A1 (en) *	1983-12-08	1990-08-14	Lachmann Burkhardt	Pharmaceutical agent for breathlesness therapy and method of its production
IT1203873B (it) *	1987-04-08	1989-02-23	Chiesi Farma Spa	Composizioni farmaceutiche che lo surfattante polmonare naturale, contengono. metodo di preparazione e

1989
- 1989-07-04 DE DE3921954A patent/DE3921954A1/de not_active Withdrawn
1990
- 1990-06-29 CA CA002020209A patent/CA2020209C/en not_active Expired - Fee Related
- 1990-06-30 DK DK90112513.8T patent/DK0406732T3/da active
- 1990-06-30 DE DE59009113T patent/DE59009113D1/de not_active Expired - Lifetime
- 1990-06-30 ES ES90112513T patent/ES2072940T3/es not_active Expired - Lifetime
- 1990-06-30 EP EP90112513A patent/EP0406732B1/de not_active Expired - Lifetime
- 1990-06-30 AT AT90112513T patent/ATE122891T1/de not_active IP Right Cessation
- 1990-07-02 DD DD90342432A patent/DD297916A5/de not_active IP Right Cessation
- 1990-07-02 PL PL90285904A patent/PL164434B1/pl not_active IP Right Cessation
- 1990-07-03 PT PT94574A patent/PT94574B/pt not_active IP Right Cessation
- 1990-07-03 JP JP02176092A patent/JP3103582B2/ja not_active Expired - Fee Related
- 1990-07-03 PH PH40776A patent/PH30232A/en unknown
- 1990-07-03 NO NO902961A patent/NO180620C/no unknown
- 1990-07-03 FI FI903341A patent/FI95655C/fi active IP Right Grant
- 1990-07-03 NZ NZ242869A patent/NZ242869A/en unknown
- 1990-07-03 NZ NZ234341A patent/NZ234341A/en unknown
- 1990-07-03 ZA ZA905182A patent/ZA905182B/xx unknown
- 1990-07-03 HU HU904077A patent/HU205004B/hu not_active IP Right Cessation
- 1990-07-03 IL IL9496190A patent/IL94961A/en not_active IP Right Cessation
- 1990-07-03 UA UA5010226A patent/UA26313A/uk unknown
- 1990-07-03 IE IE240890A patent/IE68448B1/en not_active IP Right Cessation
- 1990-07-04 AU AU58676/90A patent/AU623538B2/en not_active Ceased
- 1990-07-04 KR KR1019900010052A patent/KR0162642B1/ko not_active Expired - Fee Related
1991
- 1991-12-09 RU SU915010226A patent/RU2077880C1/ru not_active IP Right Cessation
1995
- 1995-05-01 US US08/432,386 patent/US5552161A/en not_active Expired - Lifetime
1997
- 1997-09-26 HK HK97101844A patent/HK1000277A1/xx unknown

Also Published As

Publication number	Publication date
PH30232A (en)	1997-02-05
EP0406732A3 (en)	1991-02-27
IE68448B1 (en)	1996-06-26
CA2020209C (en)	2000-09-12
ES2072940T3 (es)	1995-08-01
JPH0344332A (ja)	1991-02-26
PT94574A (pt)	1991-03-20
NZ242869A (en)	1997-05-26
IL94961A0 (en)	1991-06-10
DE59009113D1 (de)	1995-06-29
NO180620C (no)	1997-05-21
JP3103582B2 (ja)	2000-10-30
UA26313A (uk)	1999-08-30
FI95655C (fi)	1996-03-11
AU623538B2 (en)	1992-05-14
DE3921954A1 (de)	1991-01-17
RU2077880C1 (ru)	1997-04-27
ZA905182B (en)	1992-03-25
PT94574B (pt)	1997-02-28
NO902961D0 (no)	1990-07-03
EP0406732B1 (de)	1995-05-24
PL164434B1 (pl)	1994-07-29
FI903341A0 (fi)	1990-07-03
IL94961A (en)	1994-10-21
KR910002427A (ko)	1991-02-25
HK1000277A1 (en)	1998-02-20
HU205004B (en)	1992-03-30
KR0162642B1 (ko)	1998-12-01
HU904077D0 (en)	1990-12-28
NO902961L (no)	1991-01-07
CA2020209A1 (en)	1991-01-05
NZ234341A (en)	1992-07-28
EP0406732A2 (de)	1991-01-09
NO180620B (no)	1997-02-10
AU5867690A (en)	1991-01-10
DK0406732T3 (da)	1995-10-02
HUT56274A (en)	1991-08-28
US5552161A (en)	1996-09-03
ATE122891T1 (de)	1995-06-15
IE902408A1 (en)	1991-06-19
FI95655B (fi)	1995-11-30

Legal Events

Date	Code	Title	Description
2000-03-30	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
DE2601207C3 (de)	1980-07-10	Verfahren zur Herstellung einer flüssigen pharmazeutischen Zubereitung mit gesteuertem Arzneimittelabgabevermögen
EP0100910B1 (de)	1988-11-02	Lungensurfactant
DE3021006C2 (de)	1983-03-17	Oberflächenaktives Material und dieses Material enthaltendes pharmazeutisches Mittel gegen Hyalin-Membran-Erkrankung
DE3008082A1 (de)	1980-09-18	Carcinostatisches und die immunreaktion stimulierendes mittel, enthaltend lysophospholipid und phospholipid, und verfahren zur herstellung desselben
DE69305144T2 (de)	1997-02-06	Pharmazeutische Zubereitung enthaltend eine Fettemulsion von Fettmikropartikeln
EP0616801A1 (de)	1994-09-28	Verfahren zur Herstellung einer Liposomendispersion im Hochdruckbereich
DE3512926A1 (de)	1985-10-24	Verbesserung in oder bezueglich der therapie mit interleukin
DE69420872T2 (de)	2000-01-13	Hgh enthaltende pharmazeutische zubereitungen
EP0406732B1 (de)	1995-05-24	Niedrig-viskose, hochkonzentrierte Surfactant-Suspension
EP0145005B1 (de)	1989-04-12	Lungen-Surfactant, Verfahren zu seiner Herstellung und seine pharmazeutische Verwendung
DE69928279T2 (de)	2006-08-17	Lungensurfactant zubereitungen enthaltendes behandlungset
DE1195905B (de)	1965-07-01	Verfahren zum Abtrennen der Zellwaende von Mycobacterium phlei
DE3115080A1 (de)	1982-02-25	Arzneimittel fuer die orale verabreichung und verfahren zu seiner herstellung
AT397460B (de)	1994-04-25	Verfahren zur herstellung eines pharmazeutischen trockenpräparates enthaltend ein diclofenac-salz
DE69130832T2 (de)	1999-10-07	Injizierbare amphotericin b enthaltende dispersion
EP0181287A2 (de)	1986-05-14	Trockensubstanzen und stabile Suspensionen
DE2234832C2 (de)	1986-02-13	Proteinfreies Hormonkonzentrat von Säugetier-Nebenschilddrüsen, dessen Herstellung und dieses Hormonkonzentrat enthaltende pharmazeutische Präparate
DE68903670T2 (de)	1993-06-03	Physiologisch aktive, fluessige, allergenische zusammensetzungen aus biologischen rohmaterialien.
DE2546001A1 (de)	1976-04-15	Immunostimulierende phospholipide und sie enthaltende arzneimittel
DE1617279A1 (de)	1971-02-18	Verfahren zur Herstellung pharmazeutischer Praeparate zur Verhinderung der Bildung von Blutgerinnseln
EP0123142B1 (de)	1987-12-09	Verfahren zur Stabilisierung von Hämatin
DE60225117T2 (de)	2009-02-26	Behältnis mit niedrigem sauerstoffgehalt, das ff-mas enthält
DE3827472A1 (de)	1990-01-18	Verfahren zum herstellen einer waessrigen loesung von lysin-(alpha)-methyl-4-(2'-thienylcarbonyl)phenylacetat fuer die oertliche anwendung in der augenheilkunde
DE1037068B (de)	1958-08-21	Verfahren zur Herstellung von biologisch aktiven, Vitamine der B -Gruppe enthaltenden Zubereitungen
DD231189A3 (de)	1985-12-24	Mittel zur behandlung von erkrankungen, die mit veraenderungen im lungensurfactant verbunden sind, sowie verfahren zur herstellung desselben